Last month, a major study about hypertension treatment in older adults was published in the prestigious JAMA journal: “Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.”
When an important study like this is published, people often wonder: does this mean they should change the way their hypertension — or their parent’s hypertension — is being managed? Is their blood pressure (BP) at a good level? Should they be on more medication?
In this post, I’ll review the most important things to know about the newly published blood pressure research findings. Then in an upcoming post, I’ll share with you a step-by-step process you can use, to start to figure out whether an older person’s BP management plan might need to be revised.
Warning: this is one of those medically nerdy posts. But I have to write it, as it’s a foundation for later answering your questions on what your parents’ BP (or your own BP) should be, and whether you should consider a change in medication or treatment. If you just want to know the essentials, skip down to the key takeaways at the end.
SPRINT-Senior: Important New Research on Blood Pressure in Older Adults
This study is a sub-group analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) research trial that was published last fall. The original SPRINT study enrolled 9361 adults aged 50+. This recently published analysis covers the results for the 2636 participants who were aged 75 or older.
I wrote about the SPRINT study in detail last year, because it caused quite a tizzy in the mainstream media, as well as in the medical community.
Briefly: SPRINT was a large, well-done randomized trial which found that participants experienced significantly fewer cardiovascular events (e.g. heart attacks, strokes, etc) when they were treated to a goal of systolic blood pressure of 120 (intensive hypertension treatment) rather than 140 (standard hypertension treatment).
[Note: The top number in a blood pressure reading is the “systolic blood pressure” and is generally the number of interest when it comes to treating hypertension in older adults. It is abbreviated “SBP.” The lower number is the “diastolic blood pressure.” The unit of measurement for BP is “millimeters of mercury” or “mm Hg.”]
SPRINT caused a bit of an uproar, because just two years prior, in December of 2013, major new hypertension guidelines had been released. And for the first time, these had proposed a higher blood pressure treatment goal for adults aged 60 or older: 150/90. So the SPRINT results had seemed to contradict the previous guidelines, which was a bit confusing for many people and even many doctors.
[If you’d like to understand the SPRINT study in depth and also the December 2013 expert hypertension guidelines, be sure to read this post: What the New Blood Pressure Guidelines — & Research — Mean For Older Adults.” This post includes a detailed description of the BP medications used in SPRINT.]
Now this sub-group analysis of SPRINT has been published. Dubbed “SPRINT-Senior,” the study found that in these participants who were aged 75+, treating hypertension to a goal of SBP <120 resulted in better cardiovascular health outcomes, compared to treating to a goal of SBP <140.
Let’s dig into the details a bit. Remember, whenever you hear that a treatment is “better,” you should ask yourself “how much better” and “what are the risks and burdens?”
Specific results in SPRINT-Senior:
Benefits of intensive BP treatment:
During follow-up, 2.59% per year of people in the intensive-treatment group and 3.85% per year of people in the standard-treatment group experienced a significant cardiovascular “outcome event”: a heart attack, a stroke, acute decompensated heart failure, or death from cardiovascular causes.
The authors calculated that over 3.14 years, “the number needed to treat (NNT) estimate for the primary outcome was 27 and for all-cause mortality it was 41.”
In other words, if you are like the study participants, and if you decide to switch from a systolic BP goal of <140 to a goal of <120, over about three years you’ll have:
- A 1-in-27 (3.7%) chance of avoiding a cardiovascular event
- A 1-in-41 chance (2.4%) chance of avoiding death from any cause
These are actually better results than those noted in the overall SPRINT trial, which found that intensive treatment gave participants a 1-in-61 chance of avoiding a cardiovascular event and a 1-in-90 chance of avoiding death.
(This is not surprising. A risk-reducing intervention usually is more effective if people have a higher baseline risk of having the problem. Since age is a very strong risk factor for having a cardiovascular event, it makes sense that we are seeing better risk-reduction in these older participants.)
Now, a 1-in-27 chance of avoiding a cardiovascular event may not sound like much to some people. But from a prevention perspective, that’s considered a pretty good risk reduction. For comparison, when people with known cardiovascular disease take a statin to lower cholesterol and lower their risk, they have a 1-in-83 chance of avoiding death due to taking the statin.
What about in older adults who are frail? Do they benefit from a lower BP goal as well? SPRINT-Senior found that they do: the researchers did assess the frailty level of participants, and found that intensive treatment provided a similar risk reduction (for cardiovascular events and for mortality) as in non-frail participants.
Harms of intensive treatment:
Serious adverse events were fairly common in both treatment groups, affecting about 48% of participants in each group. Interestingly, the rate of specific adverse events was not statistically different between intensive treatment versus standard treatment.
A common adverse event was orthostatic hypotension, which means blood pressure that drops when a person stands up. This affected about 21% of participants in both treatment groups.
Injurious falls happened to 4.9% of the intensively treated participants and 5.5% of the standardly treated participants. Again, this difference was not statistically significant.
Summary of SPRINT-Senior
This was a large well-done study of blood pressure management in adults aged 75 or older. This sub-group analysis of SPRINT indicates that in people similar to the SPRINT participants, intensive BP control is even more likely to be beneficial as people get older.
Interestingly, SPRINT-Senior did not find that adverse events were more common in the intensively-treated group.
Caveats to Consider: Do the SPRINT-Senior Results Apply to YOU?
Before you start debating whether a 1-in-27 chance of avoiding a cardiovascular event is worth the hassle of taking an additional blood pressure medication every day, you must consider two very important issues:
- Whether you or your family member would have been eligible to be in SPRINT
- Whether you or your relative’s BP is being measured in the same way that BP was measured in SPRINT
Are you like the SPRINT participants?
A randomized control trial tells us what kind of treatment benefit we might expect assuming a patient is like the participants in the trial.
The SPRINT study, which included the SPRINT-Senior cohort, excluded participants who had a number of common conditions. Specifically, older persons with any of the following diagnoses, conditions, or circumstances were not eligible for the study:
- Past stroke
- Clinical diagnosis of dementia, and/or being on dementia medication
- People residing in a nursing home. (Assisted-living was ok.)
- Substance abuse (active or within the past 12 months)
- Symptomatic heart failure within the past 6 months or left ventricular ejection fraction (by any method) < 35%
- Polycystic kidney disease or eGFR < 20
- “Significant history of poor compliance with medications or attendance at clinic visits.”
As you can see, quite a lot of common diagnoses and circumstances were grounds for exclusion from the SPRINT study.
This means that if you or your older relative have any of the conditions listed above, we don’t know if you’d be likely to benefit from intensive blood pressure management the way the SPRINT participants did.
Are your doctors measuring BP the way the SPRINT team did?
This is the other major caveat to consider, before aiming for a SPRINT-style lower BP treatment goal.
Blood pressure was measured a very careful way that is quite different from the way patients usually have BP measured by their doctors. Here’s what they did in SPRINT:
- Had people sit down and rest for five minutes before checking BP
- Checked BP three times consecutively, using an automated BP monitor (Omron 907)
- Used the average of those three BP measurements to assess the person’s BP and determine whether medications should be adjusted up or down.
Obviously, this is not the experience that most people have in the doctor’s office. Because people had to sit quietly for a few minutes in the SPRINT protocol, this likely led to lower BP measurements than those taken under usual circumstances.
Other Major Research on Blood Pressure Lowering in People with Diabetes and Stroke
SPRINT excluded participants with a history of diabetes or stroke in part because major randomized trials had already studied the effect of intensive blood pressure treatment in those groups.
For diabetes, the major study was called ACCORD (Action to Control Cardiovascular Risk in Diabetes). It found that treating high blood pressure to a SBP goal of <120 compared to <140 did not reduce the risk of death or cardiovascular events overall, although it did reduce the risk of stroke.
For people with history of stroke, the major study evaluating the effect of treatment to a specific BP goal was called SPS3 (Secondary Prevention of Small Subcortical Strokes). This study found that randomizing participants to a goal of SBP<130, compared to SBP 130-149, did not reduce the risk of stroke overall. However, multiple other studies have found that lower blood pressure in people with past stroke does reduce the risk of future stroke. Overall, research suggests that what may be most beneficial is reducing SBP by 10-15 mm Hg, and this may be more important (or a better treatment guide) than treating to a specific BP target.
Other Important Research on Blood Pressure in Older Adults
Experts often cite two older major randomized trials, when it comes to high blood pressure treatment in older adults: SHEP (Systolic Hypertension in the Elderly) and HYVET (Hypertension in the Very Elderly Trial).
Both these trials found that reducing blood pressure with medication reduced the risk of cardiovascular disease in older adults. These studies were important, because for a long time doctors thought that high blood pressure was a “normal” part of getting old, and it was not clear that it was worth treating older people for hypertension.
So SHEP and HYVET convinced most doctors — including geriatricians — to take hypertension seriously in older adults.
That said, in SHEP and HYVET, people started with much higher baseline blood pressures than those in SPRINT. For instance in SHEP (average age 72) the baseline average SBP was 170, and after treatment the intervention group achieved an average SBP of 143. In HYVET (average age 84) the baseline average SBP was 173, and after treatment the intervention group achieved an average reduction in SBP of 15 mm Hg.
Since SHEP and HYVET demonstrated the benefit of bringing SBP down to the 140-150 range, many of us in geriatrics have focused on this, and have not thought it was likely to be beneficial to aim for still lower SBPs.
In comparison, in SPRINT-Senior, the baseline SBP at the start of the study was 142, which is quite close to the cutoff for “normal” BP (usually defined as BP<139/89). However, participants did benefit from reducing their BP further, with the intensive BP treatment group getting down to SBP 123 on average.
Hence, SPRINT-Senior does provide new information to the medical community. This has not yet been incorporated into any major blood pressure guidelines, since the SPRINT results are fairly new and the process of issuing new guidelines is slow. But the results of SPRINT-Senior will surely influence future guidelines on treating hypertension in older adults.
So what should you take away from the recent SPRINT-Senior results, and the other high-quality research on treating hypertension in older adults?
My key take-aways for patients and families are as follows:
- Treating high blood pressure in older adults does reduce the risk of cardiovascular events, including stroke and heart attacks, and also can reduce the risk of death.
- The greatest benefit probably lies in helping older people with higher SBPs (especially SBP’s over 170) achieve a reduction of 10-25 mm Hg.
- The 2013 JNC 8 Hypertension Guidelines stated that “there is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg.” This is because until SPRINT was published in 2015, there was not enough definitive evidence that in older adults, intensive BP lowering (e.g. to SBP<130) was much better than aiming for SBP<150.
- SPRINT and SPRINT-Senior provide good evidence that in people similar to the SPRINT participants (which means no history of diabetes, stroke, dementia, among other criteria), aiming for SBP< 120 does reduce the risk of cardiovascular events and death, compared to aiming for SBP < 140. For people over age 75, the study suggests that more intense BP treatment confers a 1-in-27 chance of preventing a cardiovascular event, and that being frail doesn’t interfere with this benefit.
- In considering SPRINT along with the JNC 8 guidelines, I feel that treating hypertension to a goal of SBP<150 is reasonable for most older adults. For those older adults who are similar to SPRINT participants and are willing to take extra medication for a 1-in-27 chance of avoiding a cardiovascular event, aiming for a lower SBP goal is reasonable and we should support patients who want this, assuming that there are no other reasons to avoid such intensive BP therapy.
- When considering any medication or intensification of treatment, patients and families should always consider the potential risks and burdens of treatment. Although SPRINT-Senior did not find that adverse events were more common in the intensively-treated group, some research has linked antihypertensive treatment to falls. Intensive treatment also requires taking more medication every day, which some older adults might find burdensome.
- Last but not least: If the goal is to reduce the risk of cardiovascular disease and death, we should not forget to include non-drug approaches, such as exercise, a healthy diet, and stress-reduction. For instance, a randomized trial of the Mediterranean Diet found that this diet reduced cardiovascular events. Such non-pharmacological approaches are important because they benefit health and well-being in many ways, and we shouldn’t lose sight of them as we tinker to keep BP low with medications.
Still wondering if SPRINT means you need a change in BP medications for an older relative or yourself?
Stay tuned and in an upcoming post I’ll explain a process you can use, to work with your doctors and figure out whether you are likely to benefit from a change.